文献速递膀胱癌与上尿路尿路上皮癌

新辅助化疗后膀胱切除标本残留癌患者的肿瘤学结局:一项病理分期匹配分析

Oncologic Outcomes for Patients with Residual Cancer at Cystectomy Following Neoadjuvant Chemotherapy: A Pathologic Stage-matched Analysis.
PubMed 文献 · Eur Urol · 2017-05-22

该回顾性观察研究将接受新辅助化疗(NAC)后根治性膀胱切除(RC)的患者(n=180)与仅行RC的对照(n=324)按pT/pN分期、切缘状态和RC年份匹配。在ypT0N0/pT0N0患者中两组5年无复发生存(RFS)、癌症特异性生存(CSS)和总生存(OS)无显著差异;在RC时有残留尿路上皮癌(rUCB)的患者中,NAC组5年RFS、CSS和OS显著更差,多变量分析显示NAC与更差RFS、CSS和OS独立相关。

要点

  • ypT0N0/pT0N0患者中NAC组与对照组5年RFS、CSS、OS无显著差异。
  • RC时有rUCB者中NAC组5年RFS 50% vs 63%、CSS 40% vs 59%、OS 33% vs 48%,均显著更差。
  • rUCB患者多变量分析NAC与更差RFS(HR 1.84)、CSS(HR 1.81)、OS(HR 1.57)独立相关。

核心结论

  • 对NAC达到完全缓解的患者生存结局极佳,而NAC后RC时有rUCB的患者较分期匹配的仅行RC对照预后更差。
  • 作者认为在等待进一步研究预测哪些患者经NAC可达ypT0期间,可考虑让这些rUCB患者参加评估RC后使用更新药物进行额外治疗的临床试验。

研究设计与样本

  • 回顾性观察研究,将接受NAC+RC的患者(n=180)与仅行RC的对照(n=324)按pT和pN分期、切缘状态及RC年份进行匹配。

主要发现

  • ypT0N0/pT0N0患者(n=103)中,NAC组与对照组5年RFS 90% vs 94%(p=1)、CSS 82% vs 93%(p=0.4)、OS 82% vs 82%(p=0.5),均无显著差异。
  • RC时有rUCB的患者(n=401)中,NAC组5年RFS 50% vs 63%(p=0.01)、CSS 40% vs 59%(p=0.003)、OS 33% vs 48%(p=0.02),NAC组均显著更差。
  • rUCB患者多变量分析中,接受NAC与更差RFS独立相关(HR 1.84,95%CI 1.28-2.66;p=0.001)。
  • rUCB患者多变量分析中,接受NAC与更差CSS独立相关(HR 1.81,95%CI 1.30-2.52;p<0.001)。
  • rUCB患者多变量分析中,接受NAC与更差OS独立相关(HR 1.57,95%CI 1.18-2.08;p=0.002)。

临床怎么用

  • 作者认为在等待进一步研究预测哪些患者经NAC可达ypT0期间,可考虑让NAC后RC时有rUCB的患者参加评估RC后使用更新药物进行额外治疗的临床试验。

局限性

  • 局限性包括回顾性观察设计可能带来选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: While it has been demonstrated that receipt of neoadjuvant chemotherapy (NAC) before radical cystectomy (RC) improves survival compared to RC alone, the driving factor for this benefit may be from patients with ypT0 status at surgery. Meanwhile, the implications of having residual urothelial carcinoma of the bladder (rUCB) at RC after NAC are less clear. We therefore evaluated whether survival differed between patients with rUCB at RC after NAC and stage-matched controls who underwent RC alone. Patients who underwent NAC + RC (n = 180) were matched to controls who underwent RC alone (n=324) on the basis of pT and pN stage, margin status, and year of RC. The 5-yr recurrence-free survival (RFS; 90% vs 94%; p=1), cancer-specific survival (CSS; 82% vs 93%; p=0.4), and overall survival (OS; 82% vs 82%; p=0.5) were not significantly different between the NAC and control groups for patients with ypT0N0/pT0N0 disease (n=103). Conversely, among patients with rUCB at RC (n=401), patients who received NAC had significantly worse 5-yr RFS (50% vs 63%; p=0.01), CSS (40% vs 59%; p=0.003), and OS (33% vs 48%; p=0.02). On multivariable analysis for patients with rUCB, NAC receipt remained independently associated with worse RFS (hazard ratio [HR] 1.84, 95% confidence interval [CI] 1.28-2.66; p=0.001), CSS (HR 1.81, 95% CI 1.30-2.52; p<0.001), and OS (HR 1.57, 95% CI 1.18-2.08; p=0.002). Limitations include potential for selection bias owing to the retrospective observational design. Thus, while patients who achieve a complete response to NAC have excellent survival outcomes, those with rUCB after NAC have a worse prognosis compared to stage-matched controls undergoing RC alone. It may be worthwhile considering these patients for clinical trials evaluating the role of additional treatments after RC using newer agents while we await further research on predicting which patients achieve ypT0 status from NAC before RC. PATIENT SUMMARY: On surgical removal of the bladder, patients without residual bladder cancer after neoadjuvant chemotherapy have excellent survival outcomes. However, patients with residual cancer after neoadjuvant chemotherapy and surgery have worse outcomes compared to patients undergoing surgery alone. These patients should therefore be considered for additional treatments after surgery using newer agents while we await further research on predicting which patients will benefit from neoadjuvant chemotherapy before bladder removal for cancer.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Bhindi B, Frank I, Mason RJ, et al. Oncologic Outcomes for Patients with Residual Cancer at Cystectomy Following Neoadjuvant Chemotherapy: A Pathologic Stage-matched Analysis. Eur Urol. 2017. PMID: 28545841. doi:10.1016/j.eururo.2017.05.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。